Shanghai, China. December 27, 2022. Shanghai Zhimeng Biopharma, Inc. (“Zhimeng”), an innovation-driven biopharmaceutical company focused on the development of innovative drugs for the treatment of chronic hepatitis B and central nervous system diseases, announced dosing of the first participant in Phase II study of its novel HBV capsid assembly modulator Canocapavir (ZM-H1505R) in China/Hong Kong.

Following the completion of a Phase Ia study of ZM-H1505R in the United States in 2021 and a Phase Ib study in China in 2022, Zhimeng initiated the Phase IIa trial of ZM-H1505R in China/Hong Kong in August 2022, which is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ZM-H1505R in combination with Entecavir (ETV) compared with ETV monotherapy in patients with chronic hepatitis B who have been receiving ETV monotherapy for at least 12 months. Zhimeng expects to receive the topline results from this trial in the middle of 2023.